Fezolinetant (Veozah) is a central nervous system agent that works as an antagonist at the neurokinin 3 (NK3) receptor. This action inhibits neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron which alters activity in the thermoregulatory...
The FDA has been busy this year reviewing new medications. As a practicing pharmacist, it is hard to remember everything so I wanted to outline the top 5 drug approvals in 2024 that may impact ambulatory care and geriatrics. Without further ado, here’s my top 5...
Neffy is the brand name for intranasal epinephrine that can be used for type I allergic reactions such as anaphylaxis. In this article, we will highlight some of the differences and similarities between Neffy and Epipen. Neffy was approved for patients who weigh over...
I’ve encountered a significant proportion of patients who are on chronic benzodiazepines. Drug interactions, adverse effects, and other risks to my geriatric patient population are significant when using this class of medication. Benzodiazepine withdrawal is...
On November 1, 2023, the U.S. Food and Drug Administration (FDA) approved VOQUEZNA® (vonoprazan) as a new treatment for the healing and maintenance of erosive esophagitis and the relief of heartburn associated with erosive esophagitis in adults. This FDA approval...
Weight loss has been an essential area in which many pharmaceutical companies have made interventions by providing effective medications that can assist patients dealing with obesity. In this article, we will compare the newly approved weight loss medication Zepbound...
